BioSpace News Archive

Infections caused by drug-resistant bacteria kill nearly as many people worldwide as HIV and malaria combined.

Laurence F. Doud III, the former chief executive officer of Rochester Drug Co-Operative, Inc. (RDC), one of the 10 largest pharmaceutical distributors in the United States, ignored what U.S. prosecutors have called “serious red flags” surrounding the sale of opioid drugs.

Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.

Merck announced that Frank Clyburn, executive vice president and president of human health, will be leaving the company on February 1, 2022.

The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers.

Transgene and BioInvent International AB jointly announced the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.

BioInvent International AB and Transgene jointly announce the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.

Immunovia AB announces that Philipp Mathieu has been appointed acting CEO and President with immediate effect.

NeoDynamics AB, a medtech company dedicated to advancing diagnosis and care of breast cancer, will present results from the PULSE study illustrating the benefits of the novel biopsy device NeoNavia in challenging axillary lymph nodes, at the SBI/ACR Breast Imaging Symposium in Savannah, Georgia, taking place on May 16-19.

ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital.